Monday, 24 March 2014

Obesity - Current and Future Players, New Report Launched

Obesity - Current and Future Players

Obesity - Current and Future Players report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Publisher’s team of industry experts.

Scope
  • Investigation of current and future market competition for obesity
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis

Reasons to buy
  • Gain a high level view of the trends shaping and driving obesity market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What’s the next big thing in the global obesity market landscape? Identify, understand and capitalize

Spanning Over 99 pages, 67 tables, 2 figures, “Obesity - Current and Future Players” report covering the Market Outlook, Current and Future Players, Appendix. The report covered 15 companies - Orexigen Therapeutics, Novo Nordisk, Takeda Pharmaceutical Company, Shionogi, Roche Holdings, Vivus, Arena Pharmaceuticals and Eisai, Allergan, Apollo Endosurgery, Aspire Bariatrics, Agency for Medical Innovation, Bariatric Solutions, Baronova, BaroSense, BFKW.

See more at: http://mrr.cm/Z3f

Find All Diseases at: http://www.marketresearchreports.com/diseases    

For regular industry updates subscribe to our newsletter at: 

No comments:

Post a Comment

Note: only a member of this blog may post a comment.